Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K report on June 13, 2018, detailing the outcomes of its Annual Meeting of Shareholders held on June 8, 2018. The primary focus of this filing is the voting results on key corporate matters, providing shareholders with transparency on the company's governance and oversight. The company has confirmed the election of its Class III directors and the ratification of its independent registered public accounting firm.
Key Highlights
- 1Shareholders re-elected Arthur F. Ryan, George L. Sing, and Marc Tessier-Lavigne, Ph.D. as Class III directors, with all nominees receiving substantial majority support.
- 2The appointment of PricewaterhouseCoopers LLP as Regeneron's independent registered public accounting firm for the fiscal year ending December 31, 2018, was overwhelmingly ratified by shareholders.
- 3Director election results show high approval rates, indicating shareholder confidence in the current board's leadership and strategy.
- 4The ratification of the accounting firm underscores shareholder trust in the company's financial reporting and audit processes.
- 5The filing confirms that Regeneron held its Annual Meeting of Shareholders on June 8, 2018, as scheduled.
- 6Broker non-votes were reported for the director elections, a common occurrence and a standard disclosure in such filings.